This article is a correction to:
Assessment of mesenchymal stem/stromal cell-based therapy in K/BxN serum transfer-induced arthritis
Mercedes Lopez-Santalla
Carmen Conde
Angela Rodriguez-Trillo
Marina I. Garin- 1Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
- 2Centre for Biomedical Network Research on Rare Diseases (CIBER-ER) and Advanced Therapy Unit, Madrid, Spain
- 3Advanced Therapy Unit, Health Research Institute- Fundación Jiménez Díaz, University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 4Laboratorio de Reumatología Experimental y Observacional, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela (CHUS), Servicio Gallego de Salud (SERGAS), Santiago de Compostela, Spain
A Corrigendum on
Assessment of mesenchymal stem/stromal cell-based therapy in K/BxN serum transfer-induced arthritis
By Lopez-Santalla M, Conde C, Rodriguez-Trillo A and Garin MI (2022). Front. Immunol. 13:943293. doi: 10.3389/fimmu.2022.943293
In the published article, there was a mistake in the Funding statement. The Funding statement for the “Instituto de Salud Carlos III (ISCIII)” was displayed as “Instituto de Salud Carlos III (ISCIII)” (PIE15/00048, PI17/01161, PI21/01441, PI20/01266, RICORS; RD21/0017/00’.
The correct statement is as follows:
‘This work was supported by grants from “Instituto de Salud Carlos III (ISCIII)”, co-funded by the European Union (PIE15/00048, PI17/01161, PI21/01441, PI20/01266, RICORS; RD21/0017/00; funded by European Union-NextGenerationEU. Plan de Recuperación Transformación y siliencia) and Comunidad de Madrid (AvanCell, B2017/BMD-3692). CIBERER is an initiative of the “Instituto de Salud Carlos III” and the European Regional Development Fund (ERDF)’.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: mesenchymal stem/stromal cell-based therapy, K/BxN serum transfer-induced arthritis, joint inflammation, cell therapy, immunomodulation
Citation: Lopez-Santalla M, Conde C, Rodriguez-Trillo A and Garin MI (2024) Corrigendum: Assessment of mesenchymal stem/stromal cell-based therapy in K/BxN serum transfer-induced arthritis. Front. Immunol. 15:1384171. doi: 10.3389/fimmu.2024.1384171
Received: 08 February 2024; Accepted: 26 April 2024;
Published: 08 May 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Lopez-Santalla, Conde, Rodriguez-Trillo and Garin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Marina I. Garin, marina.garin@ciemat.es; Mercedes Lopez-Santalla, mercedes.lopezsantalla@ciemat.es